Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy ...

Pascal Kraft
Nov 22, 2022
1 min read

Updated: Apr 3, 2023

Authors: Katrin Rupalla, Michel Janicot, Alexej Schmidt, Iris Helfrich, Bernhard B. Singer

Full Title: Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy, and significantly increases tumor-associated B-cell population in syngeneic liver Hepa1-6 tumor microenvironment

This poster was presented at the SITC 2022.

2023 CIMT Annual Meeting Poster Presentation

Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis ...

Authors: Mitsuro Kanda, Dai Shimizu, Koichi Sawaki, Shunsuke Nakamura, Shinichi Umeda, Takashi Miwa, Haruyoshi Tanaka, Chie Tanaka,...

Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK ...

Authors: Iris Helfrich and Bernhard B. Singer Full Title: Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its...

Comments